Gemcitabine (CAS 95058-81-4) is a high-purity antitumor API, a potent pyrimidine antimetabolite designed for targeted cancer therapy. With a precise molecular structure, it interferes with tumor cell DNA synthesis and replication, effectively inhibiting the proliferation of malignant cells and inducing apoptosis.
Produced under strict GMP standards, this API ensures consistent purity (≥99%), potency, and stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for pancreatic cancer, non-small cell lung cancer, bladder cancer, and breast cancer treatment, catering to the needs of pharmaceutical manufacturers and research institutions focusing on antitumor pharmaceutical R&D.
Its unique antimetabolite mechanism minimizes damage to normal cells while maximizing tumor-inhibiting efficacy, balancing therapeutic effect with safety. As a key raw material in clinical chemotherapy, Gemcitabine delivers reliable performance for both preclinical research and large-scale pharmaceutical production, supporting the development of effective antitumor treatments.
